Ibrunat Capsule: For Patients Managing Relapsed/Refractory Multiple Myeloma

Ibrunat Capsule contains Ibrutinib (140mg), a targeted therapy used to treat certain types of B-cell malignancies, including relapsed or refractory multiple myeloma. This medication inhibits the activity of Bruton's tyrosine kinase (BTK), an enzyme involved in B-cell signaling and proliferation.

By targeting BTK, Ibrutinib reduces the numbers of cancer cells and helps slow disease progression. It is typically used when other treatments have failed. Ibrunat Capsule is taken orally by patients and requires close medical supervision due to its potential side effects.

Important Considerations:

* This medication should only be taken under the guidance of a qualified healthcare professional.
* Ensure you understand all information regarding dosage, administration, and potential interactions with other medications before starting treatment.
* It is crucial to report any adverse reactions immediately to your doctor or pharmacist.

This detailed description provides essential information for patients and caregivers while adhering to professional medicine guidelines. It emphasizes safety and the importance of a qualified medical opinion.